Patients with symptomatic multiple myeloma (MM) following induction and conditioning therapy and autologous stem cell transplant (ASCT) may derive survival benefit from maintenance therapy with ixazomib, according to the phase III TOURMALINE-MM3* trial.
The addition of daratumumab to lenalidomide and dexamethasone improved progression-free survival (PFS) in patients newly diagnosed with multiple myeloma (MM) who were ineligible for a stem cell transplant, according to interim results of the phase III multinational MAIA* trial.
Bortezomib in combination with thalidomide plus dexamethasone (VTD) significantly improves progression-free survival (PFS) and overall survival (OS) vs thalidomide plus dexamethasone (TD) alone in patients with newly diagnosed multiple myeloma (MM) undergoing double autologous stem cell transplantation (ASCT), 10-year results of the GIMEMA-MMY-3006 trial have shown.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
Implementation of the collaborative care in a rheumatoid arthritis (RA) clinic has led to improvements in nonbiologic disease-modifying antirheumatic drugs (nb-DMARDs) optimization, adherence to safety recommendations on nb-DMARD monitoring and detection of adverse drug events in RA patients, according to a Singapore study.
Use of menopausal hormone therapy (MHT) was associated with a significantly increased risk of invasive breast cancer, which became progressively greater with longer duration of use, a meta-analysis of worldwide prospective epidemiological studies has shown.